

Kyorin and Lunatus partner to launch Lasvic tablets in nine Middle Eastern countries

08 January 2026 | News

Lasvic is an oral fluoroquinolone antibacterial agent for respiratory and ENT infections



Japan's Kyorin Pharmaceutical has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO for Lasvic tablets (Lascufloxacin hydrochloride).

Under the terms of this agreement, Lunatus will be the exclusive partner of the Product in Saudi Arabia, the UAE, Kuwait, Bahrain, Qatar, Oman, Iraq, Lebanon, and Jordan, and Kyorin will register as the Marketing Authorisation Holder (MAH) in each country and supply the Product to Lunatus.

The product is an oral fluoroquinolone antibacterial agent developed by Kyorin for respiratory and otorhinolaryngology (ear, nose, and throat: ENT) infections. It is designed to concentrate effectively in lung and ENT tissues while maintaining low systemic exposure, providing potent antibacterial activity at the site of infection.

Lasvic shows favorable activity against *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Mycoplasma pneumoniae*, oral streptococci and anaerobes, which are mentioned as pathogens detected in community-acquired pneumonia (CAP), as noted in clinical guidelines.